says Bobby who?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks - out at 1.18 for a nice scalp!
Does YOKU have a bottom
trading again?
Tos'd
Gonna take a position here....
Only if I can do the opposite
Does anyone like UNG here for swing trade bounce?
PERY gonna move higher?
Looks like it wants more bounce.
Doing great on a bloody day...
Thoughts?
gracias
BTW - Tos'd
did earnings come out for pery or just downgrade?
Feel free to short it here...
:)
It will bounce monday.
seems excessive, no?
was it earnings that sent it?
bucket
HIMX - volume before price?
Date : 11/16/2011 @ 11:02AM
Source : PR Newswire
Stock : Cmg Holdings (QB) (CMGO)
Quote : 0.017 -0.001 (-5.56%) @ 11:11AM
CMG Holdings Group Inc. (CMGO) Announces Opening of New Office
print
Cmg Holdings (QB) (USOTC:CMGO)
Intraday Stock Chart
Today : Wednesday 16 November 2011
CMG Holdings Group Inc. (CMGO) (OTCQB:CMGO.PK) www.cmgholdingsinc.com, CMG Holdings Group Inc. is a full service marketing communications holding company operating in the sectors of digital media, alternative advertising, new media marketing services, event management and commercial rights that has announced it has opened an office in New Haven, CT. The move expands CMGO's digital media and digital coupon operations as well as its interactive television and video production and digital advertising operations across Connecticut and in the New England arena. CMGO already has office locations in New York, Chicago, Tucson and Miami and this expansion move will allow marketing communications company to grow even more in the future. CMGO plans to expand its digital coupon operations and digital media presence in New Haven and add jobs across the state as the company launches their digital coupon platform across New England.
"We are pleased to announce the opening of our office in New Haven and look forward to the continued expansion within the state of Connecticut," said Jim Ennis, Chief Operating Officer, CMG Holdings Group Inc. "One of the reasons we are excited to expand into New Haven and Connecticut is their commitment to the growth of the digital media industry. Having a presence in New Haven will allow us to attract highly-skilled digital media professionals who are familiar with Connecticut and New England."
About CMG Holdings Group Inc. (CMGO):
CMG Holdings Group Inc. is a full service marketing and communications holding company. CMGO's mission is to build a national platform of exceptional companies that deliver solutions in the areas of alternative advertising, new media marketing services, commercial rights, and talent management. CMGO is seeking to expand its national presence via its acquired companies, capitalizing on their intellectual properties, patents, sales and marketing, new product development and continued operations via economic recovery. CMGO operates two wholly-owned subsidiaries, XA, The Experiential Agency, Inc. and Audio Eye, Inc.
For more information, please visit: www.cmgholdingsinc.com
About XA (XA):
XA, The Experiential Agency, Inc. is a wholly-owned subsidiary of CMG Holdings Group Inc. and has offices in Chicago and New York from which it provides corporations and highly visible brands with comprehensive event marketing, design, public relations and production services. The XA brand has a 20 year history and its team has been the creative force behind prestigious, national projects for such clients as NBC Universal, Unicef, Harrah's Entertainment, Conde Nast, McDonalds, W Hotels, Emirates Airline and Ritz Carlton.
For more information please visit: www.expagency.com and www.xasocial.com
About AudioEye, Inc. (AudioEye):
AudioEye, Inc., founded in 2003, is a wholly-owned subsidiary of CMG Holdings Group Inc. with offices in Tucson and Chicago. AudioEye has developed patented, Internet content publication and distribution software enabling conversion of any media into accessible formats and allowing for real time distribution to end users on any Internet connected device. Audio Eye is focused on creating better and more comprehensive access to Internet, print, broadcast and other media to all people regardless of their network connection, device, location, or any disabilities or disadvantages an individual may have. Audio Eye solutions include comprehensive E-Learning and E-Commerce systems as well as a variety of Internet publishing products and services that enable customers to create and deliver accessible, highly scalable web-based applications.
For more information please visit: www.audioeye.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words 'believes,' 'expects,' 'intends,' 'will,' 'anticipated,' or 'may,' and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties. It is possible that the assumptions made by management are not necessarily the most likely and may not materialize. In addition, other important factors that could cause actual results to differ materially include the following: business conditions and the amount of growth in the company's industry and general economy; competitive factors; ability to attract and retain personnel; the price of the Company's stock; and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-K; its quarterly reports on Forms 10-Q; and any reports on Form 8-K. CMG Holdings Group, Inc. (OTC QB:CMGO.PK) takes no obligation to update or correct forward-looking statements and also takes no obligation to update or correct information prepared by third parties that is not paid for by the Company.
Contact: CMG Holdings Group Inc.Jim Ennis5601 Biscayne Boulevard Miami, FL 33137305-751-0588JEnnis@CreativeManagementGroup.com
SOURCE CMG Holdings Group Inc.
Please make it stop
UGH!
EDGR seems oversold here.
just watched that.
Pathetic...
PROT 8K out
Section 1 – Registrant’s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
On November 15, 2011, Proteonomix, Inc. (the “Issuer”) today entered into an agreement with The University of Miami (the “University”), a premier educational institution, to conduct a FDA human clinical trial, in patients afflicted with End Stage Liver Disease (“ESLD”), of the Issuer’s UMK-121 Biopharmaceutical Stem Cell Technology (“UMK-121”) which is a proprietary technology based upon existing FDA approved drugs. The Issuer sublicensed UMK-121 to its wholly owned subsidiary THOR BioPharma. The Issuer is required to pay $105,000 to the University and the University will absorb all other costs associated with the study. The Issuer has agreed to pay a 3% net royalty in the event of commercialization of UMK-121.
Exhibit 10.59 Agreement Between Issuer and The University of Miami dated November 15, 2011.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROTEONOMIX, INC.
Dated: November 15, 2011
By:/s/Michael Cohen
Name: Michael Cohen
President
RESEARCH AGREEMENT
This Research Agreement (the “Agreement”) made this 15th day of November, 2011, (“Effective Date”) by and between Proteonomix Inc., located at 187 Mill Lane, Mountainside, NJ 07092 (“Company”) and University of Miami, a not-for-profit corporation having administrative offices at 1400 NW 10th Ave, 10th Floor, Miami, FL 33136 (“Institution”). (Company and Institution may be referred to individually as a “Party” and jointly as “Parties”).
WHEREAS, Andreas G. Tzakis, M.D., Ph.D. and Ian K. McNiece, Ph.D., employees of Institution, acting as the Principal Investigators for the Study (“Principal Investigators”), intend to conduct an investigator initiated and sponsored entitled: “UMK 121 in Patients with Liver Disease” (the “Study”); and
WHEREAS, the research contemplated by this Agreement is of mutual interest and benefit to Institution and Company; and
WHEREAS, Company is willing to provide partial funding support to Institution for the research described in Exhibit A attached hereto and incorporated by reference.
NOW, THEREFORE, in consideration of the premises and the mutual promises and covenants expressed herein and for other good and valuable consideration, the Parties agree as follows.
I. Responsibilities of Company. Company agrees to provide Institution with partial funding in support of the Study in accordance with the schedule listed in Exhibit A, attached hereto and incorporated by reference. Institution will use Company-provided funds solely for purposes of the Study.
II. Responsibilities of Institution.
II.1. Institution shall perform the Study in compliance with all laws and regulations that apply to the Study (“Applicable Law”), including, but not limited to 21 CFR Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards), and 42 CFR Parts 160 and 164 (the HIPAA Privacy Rule). Neither Party nor the Principal Investigators shall use any biological materials for any purposes not allowed by the protocol, the informed consent document, and the HIPAA authorization signed by the subject providing the material. Any biological materials remaining at the end of the Study shall be destroyed or handled consistent with the informed consent form or HIPAA authorization under which they were obtained.
II.2. Principal Investigators shall perform the Study as described in the final protocol developed by Principal Investigators, listed in Exhibit B (“Protocol”). The Principal Investigators shall submit the Protocol for review and approval to the appropriate review authorities, including, among others, the Institutional Review Board ("IRB") having jurisdiction over the facilities in which the Study will be conducted. Institution and Principal Investigators shall provide Company with written evidence of review and approval of the Study by the IRB prior to the initiation of the Study at Institution and, if applicable, the IRB’s continuing review and approval of the Study. The Study shall be conducted in accordance with the Protocol, as approved by the IRB, as the same may be changed from time-to-time in accordance with prudent research practices. Changes to the Protocol may be made (a) in accordance with the procedures outlined in the Protocol, or (b) by agreement of the Institution, Company and the Principal
1
Investigators. Changes to the Protocol shall be accompanied by such notification, review, and/or approval of the IRB as may be required by applicable law and/or the Protocol.
II.3. All case report forms, reports, publications and data generated during the course of this Study (the “Study Data”) are the property of Institution and may be used by Institution for any purpose whatsoever consistent with the approved informed consent documents and Applicable Law. Notwithstanding the above, after Institution publishes the results of the Study in accordance with Article VI, which the Institution shall use reasonable efforts to publish not more than three (3) months following the termination of this Study, Company may use the Study Data for internal research and development purposes.
II.4. Institution shall maintain records and data related to this Agreement in compliance with all applicable requirements, including without limitation, the Agreement and any Applicable Laws.
II.5. If for any reason a Principal Investigator becomes unavailable to conduct the Study, Institution shall promptly so notify Company. If the parties cannot agree upon a mutually acceptable successor to Principal Investigator, all further enrollments of subjects into the Study shall immediately cease and this Agreement may be terminated by either party.
II.6. After completion of the Study, Principal Investigators shall publish the results of the Study in accordance with Article VI below.
III. Term and Termination.
III.1. The term of this Agreement shall begin on the Effective Date and shall continue for a period of two (2) years unless terminated earlier as provided for herein (the “Term”).
III.2. The Agreement may be terminated by Institution at any time upon thirty (30) days prior written notice. Additionally, either Party may terminate this Agreement upon the breach of any term of this Agreement if said breach remains uncured within thirty (30) days upon receiving notice thereof. Additionally, either Party may terminate this Agreement immediately if necessary to protect the health, safety or welfare of Study subjects.
III.3. Upon receipt of any notice of termination or suspension, Institution and Principal Investigators agree that no additional Study subjects will be enrolled in the Study. Any Study subjects already enrolled in the Study will be phased-out as deemed appropriate by Company and Principal Investigators.
III.4. Upon termination, Company shall pay all costs accrued by Institution in accordance with Exhibit A, including, but not limited to, study activities, partial or complete, that Institution performed prior to termination, non-cancelable third-party obligations, medically-necessary continuing care of Subjects, and reasonable costs incurred because of the cancellation, suspension or early termination, and other non-cancelable obligations for the term of the Agreement.
III.5. The obligations of the Parties under Sections 2.3 2.4, 3.3, 3.4, 3.5, Articles IV for the time period set forth therein, V, VI for the time periods set forth therein; VII, VIII, IX, XIV and XVII shall survive the expiration or termination of this Agreement as well as any other terms which by their intent or meaning are intended to so survive.
IV.
2
Confidential Information.
IV.1. For the purposes of this Agreement, “Confidential Information” includes but is not limited to information which is not generally available to the public and which in nature is confidential and proprietary to the disclosing party, including, without limitation, information relating to Company’s and Institutions research and development, clinical trials, manufacturing processes, operations, business plans, market analysis and product concepts, the Study drug and all information related thereto, study material, ideas and developments. Confidential Information also includes any reports or data generated under this Agreement, for example without limitation, any Study Report or Study Data generated under this Agreement, and the Protocol. The Institution will have the first right to publically present the Study Report and Study Data. Once the Institution publically presents the Study Report or Study Data, such Report or Data will no longer be considered Confidential Information. Confidential Information includes not only written information, copies, CD Rom, abstracts or summaries thereof or references thereto in other documents provided by the disclosing party, but also information transferred orally, electronically or by other means.
IV.2. The receiving party shall not disclose such Confidential Information to any third party or use such information for any purpose other than the performance of this Agreement without the prior written consent of the disclosing party. The receiving party agrees to protect said Confidential Information in a manner consistent with its procedures for protecting other confidential information The Parties agree that the Confidential Information may be disclosed to employees and agents of the receiving party on a need to know basis in the performance of the Study, and the receiving party shall make such persons aware of the confidentiality obligations set forth in this Article IV and shall be responsible for any breach of these obligations by any such person.
IV.3. The provisions of Section 4.2 shall not apply to any information that: (i) was known or used by the receiving party prior to its date of disclosure by the disclosing party as evidenced by its prior written records (ii) is published or generally known to the public, either before or after the date of the disclosure by the disclosing party to receiving party through no fault or omission on the part of the receiving party or any affiliated person; (iii) is disclosed lawfully to receiving party without breach of an obligation of confidentiality to the disclosing party by sources rightfully in possession of the information to the receiving party’s knowledge; (iv) is developed independently by the receiving party without reference to or reliance upon the Confidential Information as evidenced by its prior written records; or (v) is required to be disclosed by receiving party to comply with applicable laws, as well as the specific disclosures to be made as set forth in Exhibit C hereto, to defend or prosecute litigation or to comply with governmental regulations; provided, however, that receiving party provides prior written notice of such disclosure to the disclosing party within sufficient time to give the discloser a reasonable period to contest such order.
IV.4. The obligations of non-disclosure and non-use contained herein shall continue with respect to all Confidential Information for a period of five (5) years from the date of termination or expiration of this Agreement.
V.
3
Intellectual Property and Inventions.
V.1. Pre-existing Intellectual Property. Ownership of inventions, discoveries, works of authorship and other developments existing as of the Effective Date hereof, together with all patents, copyrights, Company’s and/or Institution’s respective Confidential Information, trade secret rights and other intellectual property rights therein (collectively, “Pre-existing Intellectual Property”), is not affected by this Agreement, and neither Institution nor Company shall have any claims to or rights in any Pre-existing Intellectual Property owned, controlled, licensed to, and/or subject to assignment to the other Party, except as may be otherwise expressly provided in any other written agreement between the Parties.
V.2. Inventions. For purposes hereof, the term “Inventions” means all inventions, discoveries, developments and intellectual property of any type first conceived or reduced to practice or otherwise discovered or developed by either Party or any of such entity’s personnel, whether patentable or not, in connection with performance of the Study pursuant to the Protocol or based upon Confidential Information. Title to all Inventions arising from this Study shall vest solely with Institution.
V.3. License. As to any Institution Invention directly arising from the Study, Institution and the relevant Principal Investigators shall grant Company an option, exercisable within thirty (30) days following notice of an invention, to obtain irrevocable, perpetual, non-exclusive, worldwide, royalty-free in and to such Institution Invention (the “License”), which License shall include the right to sublicense and assign. Upon Company’s exercise of its option with regard to any particular Institution Invention, Institution and Company will negotiate in good faith for up to six (6) months in an attempt to reach a license agreement satisfactory to both parties. If an agreement is not reached by the end of that period, Company’s rights to that Institution Invention will expire, and Institution may license Institution Invention to third-parties without obligation to Company. Institution grants Company, for the term of the negotiation period, a non-exclusive, worldwide, royalty-free license on Institution’s rights to the Institution Invention for Company’s internal research purposes only. Institution and the relevant Principal Investigators shall take appropriate steps to reasonably ensure that all of its Study personnel are obligated to grant the License to Company and will cooperate to effect the foregoing. Institution shall retain, at all times, a non-exclusive free license to use Institution Inventions to perform the Study, for its internal educational, non-commercial research, and patient care purposes, and to comply with any applicable laws and regulations.
VI.
Publication.
6.1
Institution shall have the right consistent with academic standards to publish or present the results of the Study provided that the manuscript, abstract or other material proposed to be published or presented (“Proposed Publication”) shall be submitted to Company at least thirty (30) days prior to submission for publication or presentation to permit Company to request removal of any of Company’s Confidential Information contained therein and to protect its rights to any patentable Company Intellectual Property. Company shall complete its review within thirty (30) days after receipt of the Proposed Publication. If Company believes that any Proposed Publication contains any information relating to any patentable Company Intellectual Property, the disclosure of such Proposed Publication shall be delayed for up to forty five (45)
4
days from the date of receipt of the Proposed Publication to permit the filing of a patent application. If Company believes that any Proposed Publication contains Company’s Confidential Information, Company shall so notify Institution and Institution shall remove any such Company Confidential Information prior to publication or presentation.
6.2
This Article VI shall survive termination or expiration of this Agreement; provided, however, the obligations of Institution under this Article VI with respect to Confidential Information shall terminate in accordance with the termination date set forth in Article IV herein.
6.3
If required, Institution shall register the Study on www.clinicaltrials.gov, or any other registry with requirements consistent with the policy of the International Committee of Medical Journal Editors (De Angelis C, et al., Clinical trial registration: a statement from the International Committee of Medical Journal Editors, Ann Intern Med 2004; 141:477-8, as amended from time to time, the “ICMJE Policy”), in a manner consistent with Institution’s guidelines regarding the ICMJE Policy.
VII.
Indemnity.
VI.
VII.
VII.1. The Company agrees to defend, hold harmless and indemnify the Institution, Principal Investigators, all Sub-investigators, Institution’s IRB, its affiliated corporations, and its and their respective directors, regents, trustees, officers, staff, employees and agents (individually and collectively the “Indemnitees”) from any and all judgments, cost, claims, action, demands, suits, liability, loss, damage or expenses including reasonable attorneys’ and experts’ fees and costs through the appellate level (“Claims”) arising from (i) Company’s failure to adhere to the terms of this Agreement, (ii) Company’s use of the Study Data and results, or (iii) Company’s negligence or misconduct; provided, however, that Company will not indemnify or hold harmless the Indemnitees for any Claims to the extent that they are directly caused by (i) the negligence or intentional misconduct of any of the Indemnitees, (ii) any violations of any written instructions from Company or its designee excluding deviations necessary to protect the health, safety or welfare of the Study subjects, or (iii) any unauthorized warranties relating to the Study Drug made by any of the Indemnitees.
7.2
In the event any such Claim is initiated, Institution shall notify Company promptly of receipt of notice of Claim in writing and shall reasonably cooperate in the defense of such lawsuit and permit Company to defend such a Claim at the expense of the Company. Company may not admit fault or liability of behalf of any Indemnitee without the Indemnitee’s prior written consent.
7.3
The Institution agrees to defend, hold harmless and indemnify the Company, its affiliated corporations, and its and their respective directors, officers, staff, employees and agents (individually and collectively the “Company Indemnitees”) from any and all judgments, cost, claims, action, demands, suits, liability, loss, damage or expenses including reasonable attorneys’ and experts’ fees and costs through the appellate level (“Company Claims”) arising from (i) Institution’s failure to adhere to the terms of this Agreement, (ii) Institution’s use of the Study Data and results, or (iii) Institution’s negligence or misconduct; provided, however, that Institution will not indemnify or hold harmless the Company Indemnitees for any Company
5
Claims to the extent that they are directly caused by (i) the negligence or intentional misconduct of any of the Company Indemnitees, (ii) any violations of any written instructions from Institution or its designee excluding deviations necessary to protect the health, safety or welfare of the Study subjects, or (iii) any unauthorized warranties relating to the Study Drug made by any of the Company Indemnitees.
7.4
In the event any such Company Claim is initiated, Company shall notify Institution promptly of receipt of notice of Company Claim in writing and shall reasonably cooperate in the defense of such lawsuit and permit Institution to defend such a Company Claim at the expense of the Institution. Institution may not admit fault or liability of behalf of any Company Indemnitee without the Company Indemnitee’s prior written consent.
I. Insurance.
8.1
Institution and its employees shall at all times be covered by general liability insurance, with limits of coverage no less than $2,000,000 per occurrence and $2,000,000 in the aggregate and professional liability insurance with limits of coverage no less than $1,000,000 per occurrence and $3,000,000 in the aggregate. Institution shall provide evidence of such coverage to Company upon request.
8.2
Company agrees to carry and keep in force, at its expense, product liability insurance with limits not less than $1,000,000 and in addition, general liability insurance with limits not less than $1,000,000 per person and $3,000,000 aggregate to cover liability for damages on account of bodily or personal injury or death to any person, or damage to property or any person. Such insurance shall not be canceled for any cause without at least thirty (30) days prior written notice to Institution. Upon written request, Company shall provide a certificate of insurance to Institution.
I. Publicity. Except as otherwise permitted under Article VI, neither Institution nor the Principal Investigators shall originate any publicity, news release or other public announcement, written or verbal, whether to the public press or otherwise, relating to this Agreement, the Protocol, the Study conducted hereunder, or to any amendment(s) thereto without the other party’s prior review and approval. The Parties agree that Company may issue press releases regarding the Study subject to Institution review and approval, and as provided in Article IV with respect to Exhibit C “Mandatory Releases”. Notwithstanding the foregoing, Institution may disclose the Company’s name, total grant amount, and a general, non-confidential title of the Study without Company’s consent in Institution’s annual reports, internal reports, or other such reports on research, and Company may disclose all non-confidential information as it deems necessary towards the commercialization of UMK 121 or for other reasons. The parties will not use the name of the other party, or a variant thereof, in any advertising or promotional material without the other party’s prior written consent, except to state that where trial was conducted and the name of the parties participating.
I. Independent Contractor. Nothing contained in this Agreement shall be construed as establishing a partnership or joint venture between Company and Institution. It is expressly understood and agreed that Institution shall at all times act in the capacity of independent contractor and not as an agent of Company.
II.
6
Agreement Modification. This Agreement may not be altered, amended or modified except by a written document signed by the Parties.
III. Assignment. Neither Party shall assign its rights or obligations under this Agreement without the prior written consent of the other Party.
IV. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of each of the Parties hereto and each Party’s respective successors and assigns.
V. Notice. All notices or other communications that are required or permitted by this Agreement shall be in writing addressed to the receiving Party’s address as set forth below or to such other address as a Party may designate by notice hereunder, and either (i) delivered by hand, (ii) sent by telex, telecopier or facsimile transmission (and promptly confirmed by personal delivery, registered or certified mail or overnight courier) (iii) sent by nationally recognized overnight courier or (iv) sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:
If to Company:
Proteonomix Inc.
187 Mill Lane, Mountainside, NJ 07092
Attn: Michael Cohen
Tel. (973) 544-6116
Fax (973) 833-0277
E-mail:
michael.cohen@proteonomix.com
If to Institution:
Attn: Suzanne Liv Page, JD
Director, CRIS
University of Miami
Miller School of Medicine
1400 N.W. 10th Ave., 10th Floor, R45
Miami, FL 33136
Tel: (305) 243-8596
Fax: (305) 243-5129
E-mail: spage3@med.miami.edu
ugly - should bounce
QPSA -20%
why the drop?
any idea?
PROT .51 News**8k***DD**FDA***
8k filed on FDA style NEWS...
Based in Washington, D.C., the Personal Care Product Council (“PCPC”) has funded the Cosmetic Ingredient Review (“CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients (“INCI”) name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8238146
This is HUGE news...with a 7.4 million O/S and 5.1 million float...we have the chance to see much much HIGHER..
PROT REPORT HIGHLIGHTS: http://www.bccresearch.com/report/HLC060A.html
* The global anti-aging market for the boomer generation was worth $162.2 billion in 2008. This should reach $274.5 billion in 2013, for compound annual growth rate (CAGR) of 11.1%.
* The disease segment generated $66.0 billion in 2008. This is expected to grow at a CAGR of 12.5% to reach $119.2 billion in 2013.
* The appearance segment generated $64.4 billion in 2008. This segment should increase to $105.4 billion in 2013, for a CAGR of 10.4%.
where is the news?
you missed it hon
Did I win the post contest?
fudge
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...
Date : 11/11/2011 @ 4:00PM
Source : MarketWire
Stock : Proteonomix (PROT)
Quote : 0.51 0.065 (14.61%) @ 3:57PM
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...
print
Proteonomix (OTCBB:PROT)
Intraday Stock Chart
Today : Friday 11 November 2011
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Cosmetic Ingredients Review Board ("CIR") has approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States.
Michael Cohen, President of the Company, stated: "The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA."
Proteoderm Inc. has developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in cosmeceutical products.
Mr. Cohen continued: "We anticipate that our efforts to market the product and partner up with other cosmetic manufacturers will be greatly enhanced by the issuance of an INCI name."
Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email: Email Contact
The stock needs to bounce off here or we are screwed
tos'd
NOEC down 45%
gracias
:)
what's the story on that one?
stock goodies pump
no thanks
tos'd
did the clocks change?
SSYO launching here